Advances in pathophysiology, diagnosis and treatment of adult severe-associated thrombotic microangiopathy.
10.3760/cma.j.cn121430-20230808-00596
- Author:
Hua XU
1
;
Yongqiang WANG
;
Hongmei GAO
Author Information
1. Department of Critical Care Medicine, Tianjin First Center Hospital, Key Laboratory for Critical Care Medicine of the Ministry of Health, Emergency Medicine Research Institute, Tianjin 300192, China. Corresponding author: Gao Hongmei, Email: ghm182@163.com.
- Publication Type:Journal Article
- MeSH:
Adult;
Humans;
Thrombotic Microangiopathies/therapy*;
Purpura, Thrombotic Thrombocytopenic/therapy*;
Anemia, Hemolytic/therapy*;
Treatment Outcome;
Diagnosis, Differential
- From:
Chinese Critical Care Medicine
2023;35(12):1335-1339
- CountryChina
- Language:Chinese
-
Abstract:
Thrombotic microangiopathy (TMA) is a group of highly heterogeneous, acute and severe clinicopathological syndromes, characterized by microangiopathic hemolytic anemia (MAHA), thrombocytopenia and ischemic injury of end organs. TMA has the characteristics of dangerous condition, multiple organ involvement and high mortality. Patients with severe TMA need to be admitted to intensive care unit (ICU) for organ function support therapy. Early and rapid evaluation, differential diagnosis, and timely and effective treatment are the key to improve the prognosis of TMA patients. Here, we review the pathophysiological changes, diagnosis differential diagnosis, and treatment of the severe TMA in adult.
